Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases
Open Access
Abstract
Although many arenaviruses cause severe diseases with high fatality rates each year, treatment options are limited to off-label use of ribavirin, and a Food and Drug Administration (FDA)-approved vaccine is not available. To identify novel therapeutic candidates against arenaviral diseases, an RNA polymerase I-driven minigenome (MG) expression system for Lassa virus (LASV) was developed and optimized for high-throughput screening (HTS). Using this system, we screened 2595 FDA-approved compounds for inhibitors of LASV genome replication and identified multiple compounds including pixantrone maleate, a topoisomerase II inhibitor, as hits. Other tested topoisomerase II inhibitors also suppressed LASV MG activity. These topoisomerase II inhibitors also inhibited Junin virus (JUNV) MG activity and effectively limited infection by the JUNV Candid #1 strain, and siRNA knockdown of both topoisomerases (IIα and IIβ) restricted JUNV replication. These results suggest that topoisomerases II regulate arenavirus replication and can serve as molecular targets for panarenaviral replication inhibitors.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP22fk0108114, JP22fm0208101, JPMJMS2025)
- Japan Science and Technology Agency (JP22fk0108114, JP22fm0208101, JPMJMS2025)
This publication has 44 references indexed in Scilit:
- Pathogenesis of Lassa FeverViruses, 2012
- Host Cell Factors as Antiviral Targets in Arenavirus InfectionViruses, 2012
- Potent Antiviral Activity of Topoisomerase I and II Inhibitors against Kaposi's Sarcoma-Associated HerpesvirusAntimicrobial Agents and Chemotherapy, 2012
- Minigenomes, transcription and replication competent virus-like particles and beyond: Reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever virusesAntiviral Research, 2011
- Rescue from Cloned cDNAs and In Vivo Characterization of Recombinant Pathogenic Romero and Live-Attenuated Candid #1 Strains of Junin Virus, the Causative Agent of Argentine Hemorrhagic Fever DiseaseJournal of Virology, 2011
- Cap binding and immune evasion revealed by Lassa nucleoprotein structureNature, 2010
- DNA topoisomerase II, genotoxicity, and cancerMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007
- Replicon System for Lassa VirusJournal of Virology, 2004
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999
- Unexpected adverse reactions during a clinical trial in rural West AfricaAntiviral Research, 1992